Joinn Laboratories (06127) actual controller Zhou Zhiwen reduces 10.10 million shares of the company's stock.

date
18:16 23/01/2026
avatar
GMT Eight
Zhao Yan New Drug (06127) announced that on January 23, 2026, the company received a notification from one of the actual controllers, Zhou Zhiwen, regarding the reduction of the company's shares. Zhou Zhiwen reduced his holdings by a total of 4.1537 million shares through centralized bidding on the Shanghai Stock Exchange from January 22, 2026 to January 23, 2026, representing 0.55% of the company's current total share capital; and by a total of 5.95 million shares through block trading, representing 0.79% of the company's current total share capital. Following this equity change, the shareholding percentage of actual controllers Zhou Zhiwen and Feng Yuxia decreased from 32.27% to 30.93%, triggering a 1% scale change in equity.
Joinn Laboratories (06127) announced that on January 23, 2026, the company received a notification from one of the actual controlling shareholders, Zhou Zhiwen, regarding the reduction of company shares. Zhou Zhiwen sold a total of 4.1537 million shares through the Shanghai Stock Exchange by centralized bidding method between January 22, 2026 and January 23, 2026, representing 0.55% of the company's current total share capital; and sold a total of 5.95 million shares through block trading, representing 0.79% of the company's current total share capital. After this equity change, the shareholding proportion of actual controlling shareholders Zhou Zhiwen and Feng Yuxia decreased from 32.27% to 30.93%, reaching the 1% threshold for equity changes.